Suppr超能文献

肝素模拟物 RGTA-OTR4120 对放射性照射的鼠唾液腺的影响。

The effects of heparan sulphate mimetic RGTA-OTR4120 on irradiated murine salivary glands.

机构信息

Department of Oral and Maxillofacial Surgery, Erasmus MC, 3000 CA Rotterdam, The Netherlands.

出版信息

J Oral Pathol Med. 2012 Jul;41(6):477-83. doi: 10.1111/j.1600-0714.2011.01124.x. Epub 2012 Jan 10.

Abstract

BACKGROUND

This study focuses on the potential of ReGeneraTing Agent OTR4120 (RGTA-OTR4120) to treat radiation-induced damage of salivary glands. RGTAs are biopolymers designed to mimic the effects of heparan sulphate, thereby stimulation tissue repair and regeneration.

METHODS

C3H mice were irradiated with a single dose of 15 Gy in the head and neck region. RGTA-OTR4120 was injected 24 h after radiotherapy, followed by weekly injections. At 2, 6 and 10 weeks after radiotherapy, salivary flow rates were measured and animals were sacrificed to obtain parotid and submandibular glands for histology. Periodic acid Schiff stain was performed to visualize mucins that are produced by acinar cells. Amylase and total protein content were measured in saliva samples.

RESULTS

Salivary flow rates were increased at 2 weeks, but not at 6 and 10 weeks after radiotherapy with RGTA-OTR4120 administration, compared to irradiated controls. Two and 10 weeks after radiotherapy, the mucin production activity of acinar cells was increased under influence of RGTA administration. RGTA-OTR4120 did not influence amylase or total protein secretion.

CONCLUSION

RGTA-OTR4120 administration has a positive effect on salivary flow rates in irradiated mice on the short term. The effect was absent 10 weeks after radiotherapy, while at that time point, mucin producing activity of acinar cells was elevated by RGTA-OTR4120 administration. Given these results and the advantages of RGTA use in irradiated patients, further investigation on the potential of this drug to treat radiation-induced salivary gland damage, alone or in combination with other drugs, such as amifostine, is suggested.

摘要

背景

本研究聚焦于 ReGeneraTing Agent OTR4120(RGTA-OTR4120)治疗唾液腺放射性损伤的潜力。RGTAs 是一种生物聚合物,旨在模拟硫酸乙酰肝素的作用,从而刺激组织修复和再生。

方法

C3H 小鼠头颈部单次照射 15 Gy。放疗后 24 小时注射 RGTA-OTR4120,随后每周注射一次。放疗后 2、6 和 10 周,测量唾液流量,处死动物获取颌下腺和腮腺进行组织学检查。过碘酸雪夫染色显示由腺泡细胞产生的粘蛋白。测量唾液样本中的淀粉酶和总蛋白含量。

结果

与放疗对照相比,放疗后 2 周给予 RGTA-OTR4120 治疗可增加唾液流量,但在 6 周和 10 周时则没有增加。放疗后 2 周和 10 周,腺泡细胞的粘蛋白产生活性在 RGTA 给药的影响下增加。RGTA-OTR4120 不影响淀粉酶或总蛋白分泌。

结论

在短期,给予 RGTA-OTR4120 治疗可对放疗小鼠的唾液流量产生积极影响。放疗后 10 周时这种作用消失,而此时,腺泡细胞的粘蛋白产生活性则被 RGTA-OTR4120 治疗所升高。鉴于这些结果以及 RGTA 在放疗患者中的应用优势,建议进一步研究该药物单独或与其他药物(如氨磷汀)联合治疗放射性唾液腺损伤的潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验